AC Immune (NASDAQ:ACIU) Receives $9.00 Average PT from Brokerages

AC Immune (NASDAQ:ACIU) has received a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $9.00.

Several equities research analysts recently weighed in on ACIU shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of AC Immune in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th.

AC Immune Price Performance

Shares of AC Immune stock opened at $3.02 on Friday. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.00. The business’s fifty day moving average price is $3.15 and its two-hundred day moving average price is $3.03. The company has a market capitalization of $303.24 million, a P/E ratio of -3.60 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.14 million. AC Immune had a negative return on equity of 92.65% and a negative net margin of 1,977.71%. On average, research analysts expect that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AC Immune

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its stake in AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares in the last quarter. Sei Investments Co. bought a new stake in shares of AC Immune in the 2nd quarter worth $51,000. Assenagon Asset Management S.A. acquired a new stake in shares of AC Immune in the third quarter valued at $549,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune in the third quarter valued at $48,000. Finally, Susquehanna International Group LLP bought a new position in AC Immune during the third quarter valued at about $63,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.